- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00742222
Electronic Xoft Intersociety Brachytherapy Trial: Electronic Brachytherapy (EBT) For Treatment of Early Stage Breast Cancer (EXIBT)
Electronic Xoft Intersociety Brachytherapy Trial
PRINCIPAL INVESTIGATORS
- Rakesh Patel, MD- Radiation Oncologist
- Peter Beitsch, MD- Breast Surgeon
REGISTRY DESIGN
- Multicenter, non-randomized, post market registry of intracavitary accelerated partial breast irradiation in appropriately selected patients.
SAMPLE SIZE AND SITES:
- Approximately 400 patients may be enrolled.
- Up to 100 qualified U.S. sites may participate in this registry.
ENDPOINTS:
PRIMARY ENDPOINTS
- Subcutaneous Toxicities - The incidence of signs and symptoms of subcutaneous toxicities will be recorded at the following follow-up visits; at six (6) month, one (1) year, two (2) year, three (3) year, four (4) year, and five (5) year.
- Skin Toxicities - Specific toxicities that can result from radiation therapy will be recorded at each follow-up visit. The Common Terminology Criteria for Adverse Events will be used and to be recorded at each follow-up visits; at one (1) month, six (6) month, one (1) year, two (2) year, three (3) year, four (4) year, and five (5) year.
- Cosmetic Outcome - Cosmetic outcome will be recorded at the following follow-up visits; at one (1) month, six (6) month, one (1) year, two (2) year, three (3) year, four (4) year, and five (5) year. Cosmetic outcome will be assessed and graded in two ways:
- Patient Quality of Life Questionnaire - A Quality of Life Questionnaire (QOL) will be completed at the following visits; at one (1) month, six (6) month, one (1) year, two (2) year, three (3) year, four (4) year, and five (5) year.
SECONDARY ENDPOINTS
- Local-regional Breast Failure - The secondary efficacy endpoint is ipsilateral breast failure at five (5) years.
This includes:
- Ipsilateral recurrence within the initially treated volume. (Within the tumor bed)
- Ipsilateral recurrence of cancer outside of the initially treated volume. (Elsewhere Failure)
Axillary nodal recurrence
- Survival - to be recorded at each follow-up visit
- Overall Survival
Disease Free Survival
- Device Performance - to be recorded during the balloon applicator placement and during the course of the radiation treatments:
- Ability to deliver treatment
- Axxent System / Balloon Applicator performance
- TREATMENT DEVICE
The device to be used is the electronic brachytherapy system for the treatment of early stage breast cancer with intracavitary accelerated partial breast irradiation. The device manufacturer is Xoft, Incorporated. All Xoft technology cleared by the FDA for the treatment of early stage breast cancer can be used in this post market data collection registry.
OVERSIGHT COMMITTEE
Representatives from American Brachytherapy Society (ABS), American Society of Breast Surgeons (ASBS), and American College of Radiation Oncology (ACRO)will oversee study management.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Alabama
-
Tuscaloosa, Alabama, United States, 35401
- DCH Cancer Treatment Center
-
-
California
-
Montebello, California, United States, 90640
- Beverly Oncology
-
-
Florida
-
Orange Park, Florida, United States, 32073
- Florida Radiation Oncology Group
-
-
Illinois
-
Swansea, Illinois, United States, 62226
- St Elizabeth's and Memorial Cancer Center
-
-
Missouri
-
Cape Girardeau, Missouri, United States, 63703
- Cancer Institute of Cape Girardeau
-
-
New Jersey
-
Galloway, New Jersey, United States, 08205
- AtlantiCare Cancer Care Institute
-
Northfield, New Jersey, United States, 08225
- Nazha Cancer Center
-
-
Texas
-
Dallas, Texas, United States, 75230
- Dallas Surgical Group / Northpoint Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient 50 years of age or older
- Estrogen receptor positive
- Tumor size ≤ 3cm
- Tumor histology: invasive carcinoma or DCIS
- Patient is node negative
- Patient has negative surgical margins (NSABP definition, no tumor on ink) after final surgery
- Life expectancy > 5 years
Exclusion Criteria:
- Pregnancy or breast-feeding. (If appropriate, patient must use birth control during the registry.) The need for a pregnancy test is based on the physician's standard practice and will be performed according to the physician's standard of care.
- Collagen Vascular Disease
- Scleroderma
- Systemic sclerosis
- Active lupus
- Infiltrating lobular histology
- Previous ipsilateral radiation to the thorax or breast
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: single arm, treatment with FDA cleared technology
Patients who have early stage breast cancer, and are candidate for intracavitary accelerated partial breast irradiation may be considered for this study.
|
34 Gy administered over 10 fractions, twice a day times five days.
The radiation therapy treatment will be complete upon the 5th day.
Other Names:
3.4 Gy BID x 5 days
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The incidence of signs and symptoms of subcutaneous toxicities will be recorded at the following follow-up visits; six month, one year, two year, three year, four year, and five year.
Time Frame: 5 years
|
5 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Local-regional Breast Failure - Ipsilateral breast failure at five years, Including: Ipsilateral recurrence within the initially treated volume, Ipsilateral recurrence of cancer outside of the initially treated volume, and axillary nodal recurrence
Time Frame: 5 years
|
5 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Rakesh Patel, MD, University of Wisconsin Radiation Oncology Department
Publications and helpful links
General Publications
- Dickler A, Kirk MC, Seif N, Griem K, Dowlatshahi K, Francescatti D, Abrams RA. A dosimetric comparison of MammoSite high-dose-rate brachytherapy and Xoft Axxent electronic brachytherapy. Brachytherapy. 2007 Apr-Jun;6(2):164-8. doi: 10.1016/j.brachy.2007.01.005.
- Smitt MC, Kirby R. Dose-volume characteristics of a 50-kV electronic brachytherapy source for intracavitary accelerated partial breast irradiation. Brachytherapy. 2007 Jul-Sep;6(3):207-11. doi: 10.1016/j.brachy.2007.03.002.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Adenocarcinoma
- Neoplasms, Glandular and Epithelial
- Breast Diseases
- Neoplasms, Ductal, Lobular, and Medullary
- Breast Carcinoma In Situ
- Carcinoma in Situ
- Breast Neoplasms
- Carcinoma
- Carcinoma, Ductal
- Carcinoma, Intraductal, Noninfiltrating
Other Study ID Numbers
- TPR-0186
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Carcinoma
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingMetastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Locally Advanced Bladder Urothelial Carcinoma | Locally Advanced Renal Pelvis Urothelial... and other conditionsUnited States
-
National Cancer Institute (NCI)Not yet recruitingBreast Carcinoma | Breast Ductal Carcinoma In Situ | Breast Lobular Carcinoma In Situ | Estrogen Receptor-Positive Breast CarcinomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)Active, not recruitingEstrogen Receptor Positive | Ductal Breast Carcinoma In Situ | Grade 1 Invasive Breast Carcinoma | Grade 2 Invasive Breast Carcinoma | Grade 3 Invasive Breast Carcinoma | Invasive Ductal and Lobular Carcinoma In Situ | Mucinous Breast Carcinoma | Tubular Breast CarcinomaUnited States
-
Eye & ENT Hospital of Fudan UniversityChanghai Hospital; Fudan University; RenJi Hospital; Xinhua Hospital, Shanghai... and other collaboratorsRecruitingGlottic Carcinoma | Supraglottic Carcinoma | Subglottic Carcinoma | Pyriform Sinus Carcinoma | Postcricoid Carcinoma | Posterior Pharyngeal Wall CarcinomaChina
-
Ohio State University Comprehensive Cancer CenterEmbr Labs, Inc.Active, not recruitingHot Flashes | Breast Carcinoma | Breast Ductal Carcinoma In Situ | Breast Lobular Carcinoma In SituUnited States
-
Institut BergoniéCompletedIntraductal Carcinoma and Lobular Carcinoma in SituFrance
-
Mamta ParikhNational Cancer Institute (NCI); Karyopharm Therapeutics IncRecruitingMetastatic Urothelial Carcinoma | Locally Advanced Urothelial Carcinoma | Advanced Urothelial Carcinoma | Refractory Urothelial CarcinomaUnited States
-
University of UtahNational Cancer Institute (NCI)RecruitingMetastatic Urothelial Carcinoma | Locally Advanced Urothelial Carcinoma | Unresectable Urothelial Carcinoma | Infiltrating Urothelial Carcinoma, Sarcomatoid VariantUnited States
-
Roswell Park Cancer InstituteIovance Biotherapeutics, Inc.WithdrawnMetastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Unresectable Renal Pelvis Urothelial Carcinoma | Unresectable Ureter Urothelial CarcinomaUnited States
-
Xoft, Inc.Icad, Inc.WithdrawnDuctal Carcinoma In Situ | Invasive Ductal Carcinoma
Clinical Trials on Electronic Brachytherapy
-
Instituto de Investigacion Sanitaria La FeCompletedCarcinoma, Basal Cell
-
Xoft, Inc.CompletedEndometrial CancerUnited States
-
Xoft, Inc.Icad, Inc.CompletedCervical CancerUnited States
-
University of LouisvilleTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage IIA | Breast Cancer, Invasive Ductal | Invasive Mammary CarcinomaUnited States
-
Xoft, Inc.CompletedBasal Cell Carcinoma | Squamous Cell CarcinomaUnited States
-
Xoft, Inc.Icad, Inc.Active, not recruitingDuctal Carcinoma in Situ | Invasive Ductal CarcinomaUnited States, Portugal, Australia
-
Parkridge Medical CenterTerminatedGlioblastoma | GBM | Recurrent GBMUnited States
-
Xoft, Inc.Icad, Inc.WithdrawnDuctal Carcinoma In Situ | Invasive Ductal Carcinoma
-
Memorial Sloan Kettering Cancer CenterLynn Cancer InstituteActive, not recruitingSquamous Cell Carcinoma | Cutaneous Basal CellUnited States